KR20200121308A - 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 - Google Patents

비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 Download PDF

Info

Publication number
KR20200121308A
KR20200121308A KR1020207023368A KR20207023368A KR20200121308A KR 20200121308 A KR20200121308 A KR 20200121308A KR 1020207023368 A KR1020207023368 A KR 1020207023368A KR 20207023368 A KR20207023368 A KR 20207023368A KR 20200121308 A KR20200121308 A KR 20200121308A
Authority
KR
South Korea
Prior art keywords
drug
ghs
therapeutically effective
effective amount
nafld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207023368A
Other languages
English (en)
Korean (ko)
Inventor
마이클 올리버 토너
로이 쥐. 스미스
Original Assignee
루모스 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루모스 파마, 인크. filed Critical 루모스 파마, 인크.
Priority to KR1020247002905A priority Critical patent/KR20240015742A/ko
Publication of KR20200121308A publication Critical patent/KR20200121308A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207023368A 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 Ceased KR20200121308A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002905A KR20240015742A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002905A Division KR20240015742A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Publications (1)

Publication Number Publication Date
KR20200121308A true KR20200121308A (ko) 2020-10-23

Family

ID=67620042

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207023368A Ceased KR20200121308A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
KR1020247002905A Ceased KR20240015742A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247002905A Ceased KR20240015742A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Country Status (10)

Country Link
US (3) US20210059993A1 (https=)
EP (3) EP4623929A3 (https=)
JP (3) JP2021513552A (https=)
KR (2) KR20200121308A (https=)
CN (2) CN118453597A (https=)
AU (2) AU2019222736B2 (https=)
BR (1) BR112020016613A2 (https=)
CA (1) CA3088177A1 (https=)
EA (1) EA202091464A1 (https=)
WO (1) WO2019161025A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646327A (zh) * 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物
WO2022059946A1 (ko) * 2020-09-18 2022-03-24 서울대학교 산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법

Also Published As

Publication number Publication date
JP2025179056A (ja) 2025-12-09
US20250281470A1 (en) 2025-09-11
EP4623929A2 (en) 2025-10-01
CA3088177A1 (en) 2019-08-22
BR112020016613A2 (pt) 2020-12-22
EP4623929A3 (en) 2025-12-17
EP3781158A1 (en) 2021-02-24
EP4467158A2 (en) 2024-11-27
AU2019222736B2 (en) 2024-08-01
WO2019161025A1 (en) 2019-08-22
JP2021513552A (ja) 2021-05-27
AU2019222736A1 (en) 2020-07-30
EA202091464A1 (ru) 2020-12-07
CN118453597A (zh) 2024-08-09
US20210059993A1 (en) 2021-03-04
EP3781158A4 (en) 2022-03-16
CN111727041A (zh) 2020-09-29
KR20240015742A (ko) 2024-02-05
EP4467158A3 (en) 2025-02-19
US20230381158A1 (en) 2023-11-30
AU2024205599A1 (en) 2024-08-22
JP2024028337A (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
KR20200121308A (ko) 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
US20240325530A1 (en) Combination therapies
US20250241992A1 (en) Compositions and methods for treating metabolic diseases
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
US20250296973A1 (en) Treatment method using mazdutide
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
US20260069586A1 (en) Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2026090181A1 (en) Glp-1 receptor agonist combinations and use thereof for increasing weight loss while improving muscle mass and strength
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
TW202606654A (zh) 用於預防及治療肥胖及相關病狀及病症之方法
HK40118093A (en) Treatment method using mazdutide
WO2026035940A1 (en) Treatment of obesity
MX2008010141A (en) Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221101

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221101

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230302

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20221229

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230825

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230801

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230302

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221229

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20221101

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240124